Multi-Omics, Gene Editing, AI: Advancing Biomedical Research

Katarina J. Vukovic
Department of Clinical Oncology, University of Belgrade, Serbia

*Corresponding Authors**

Katarina J. Vukovic
Department of Clinical Oncology, University of Belgrade, Serbia
E-mail: katarina.vukovic@belgrade.ac.rs

Received: 01-May-2025; **Accepted:** 29-May-2025; **Published:** 29-May-2025

Introduction

RNA sequencing (RNA-Seq) technology has fundamentally transformed the landscape of gene expression analysis, providing unprecedented capabilities for comprehensive transcriptome profiling. This powerful technique elucidates intricacies of gene regulation, identifies alternative splicing events, and facilitates the discovery of novel transcripts across a diverse range of biological systems, thereby offering critical insights into cellular processes and disease states [1].

Microglia, the central nervous system's resident immune cells, are pivotal guardians of brain development, maintaining neural homeostasis, and contributing significantly to disease pathogenesis. Their proper functioning is indispensable for neural health, while their dysregulation is increasingly implicated in the etiology and progression of debilitating neuroinflammatory and neurodegenerative disorders, including Alzheimer's and Parkinson's diseases [2].

Building upon bulk RNA-Seq, advanced single-cell RNA sequencing (scRNA-Seq) offers unparalleled resolution by enabling the dissection of cellular heterogeneity within complex tissues. This high-resolution approach allows for the precise identification of distinct cell populations and characterization of their specific gene expression profiles, which is crucial for understanding nuanced disease mechanisms where cell-type-specific responses are paramount [3].

Genome-wide association studies (GWAS) have been instrumental in identifying numerous genetic loci statistically associated with disease risk. However, the subsequent challenge lies in pinpointing the actual causal genes within these broad regions and deciphering their precise functional consequences, a task often requiring complementary functional genomic data [4].

CRISPR-Cas9 gene editing technology represents a monumental scientific breakthrough, offering unprecedented precision for targeted genomic modifications. This revolutionary tool not only facilitates robust functional genomics studies by enabling precise gene knockouts or insertions but also opens transformative therapeutic avenues for a myriad of genetic diseases, promising highly specific interventions [5].

Adeno-associated virus (AAV) vectors have emerged as highly favored vehicles for in vivo gene delivery, primarily owing to their favorable safety profile characterized by low immunogenicity and their efficient capacity to transduce a wide array of cell types, including critically important neurons. The ongoing optimization of AAV serotypes and a deeper understanding of host immune responses are paramount for the successful and sustained efficacy of gene therapy applications [6].

Induced pluripotent stem cells (iPSCs) constitute a remarkably versatile and powerful model system for studying human diseases directly in vitro. These patient-specific cellular models allow for the generation of various cell types and tissues that recapitulate disease pathologies, providing an invaluable platform for drug screening, toxicology studies, and deciphering complex disease mechanisms without ethical concerns associated with direct human experimentation [7].

Proteomics, the large-scale and systematic study of proteins, serves as an essential complement to transcriptomics by offering direct insights into protein abundance, post-translational modifications, and protein-protein interactions. These molecular details are often more directly linked to ultimate cellular function and observable disease phenotypes, thus providing a crucial layer of biological information [8].

Integrating multi-omics data – encompassing genomics, transcriptomics, and proteomics – is increasingly recognized as indispensable for achieving a truly holistic and comprehensive understanding of intricate biological systems and the multifaceted complexity of disease. This synergistic approach holds immense promise for accelerating the discovery of novel biomarkers and the development of highly targeted therapeutic strategies [9].

Epigenetic modifications, such as DNA methylation and histone acetylation, exert profound regulatory control over gene expression without altering the underlying DNA sequence. Investigating these dynamic modifications adds another critical layer of complexity to understanding disease etiology, progression, and identifying potential therapeutic targets, offering new avenues for intervention [10].

Description

RNA sequencing (RNA-Seq) employs high-throughput sequencing to quantify RNA molecules, providing a detailed snapshot of gene activity across different conditions. This method is crucial for identifying differen-

Cite this article: Vukovic KJ,(2025) Multi-Omics, Gene Editing, AI: Advancing Biomedical Research. Eur J Clin Oncol 07: 7. DOI:

tially expressed genes, characterizing isoform usage, and discovering novel transcripts, making it an indispensable tool in modern molecular biology for disease research and basic science [1].

Microglia are highly dynamic cells that continuously survey their microenvironment, mediating immune responses, synaptic pruning, and debris clearance. In disease states, chronic activation or dysfunction of microglia can lead to sustained neuroinflammation, contributing to neuronal damage and accelerating the progression of neurodegenerative conditions like ALS and multiple sclerosis [2].

Single-cell RNA sequencing (scRNA-Seq) protocols involve isolating individual cells, amplifying their RNA, and sequencing it to generate cell-specific transcriptomic profiles. This approach has illuminated the heterogeneity of cell populations within tumors, brain tissues, and immune systems, revealing rare cell types and transient states that are masked in bulk analyses, which is vital for precision medicine [3].

While GWAS identifies genomic regions associated with disease, it often highlights non-coding regions or multiple genes within a locus. Integrating RNA-Seq data allows researchers to identify genes whose expression levels correlate with disease-associated genetic variants, thereby providing functional evidence and narrowing down the list of potential causal genes for further mechanistic investigation [4].

CRISPR-Cas9 technology utilizes a guide RNA to direct the Cas9 nuclease to specific DNA sequences, creating double-strand breaks that can be repaired to introduce precise genetic changes. Despite its power, ongoing efforts focus on developing high-fidelity Cas9 variants and delivery systems to minimize off-target editing and ensure therapeutic safety and efficacy in clinical applications [5].

AAV vectors demonstrate excellent transduction efficiency in various post-mitotic cells, making them ideal for gene therapy in organs like the brain, liver, and eye. Research efforts are aimed at engineering novel AAV capsids with enhanced tropism, reduced immunogenicity, and improved manufacturing scalability to overcome current limitations and expand their therapeutic utility [6].

iPSCs are generated by reprogramming somatic cells into a pluripotent state, capable of differentiating into any cell type. This technology enables the creation of disease-specific neurons, cardiomyocytes, or hepatocytes from patient biopsies, offering invaluable platforms for modeling complex genetic disorders, testing novel therapeutics, and studying drug metabolism in a relevant human context [7].

Proteomics methodologies, including mass spectrometry-based approaches, quantify protein abundance, identify post-translational modifications such as phosphorylation and glycosylation, and map protein-protein interaction networks. This information is critical for understanding cellular signaling pathways, enzymatic activities, and the direct molecular effectors of disease pathology, often providing a clearer picture than RNA levels alone [8].

The integration of multi-omics data involves sophisticated computational methods to correlate findings from genomics, transcriptomics, proteomics, and metabolomics. This holistic strategy allows for the construction of comprehensive biological networks, identification of critical regulatory hubs, and robust biomarker panels, which are instrumental for personalized medicine and stratified patient treatment [9].

Epigenetic modifications represent dynamic mechanisms that influence gene expression without altering the DNA sequence itself. Studies on DNA methylation, histone modifications, and non-coding RNAs are revealing their crucial roles in development, environmental responses, and disease susceptibility, highlighting their potential as targets for novel therapeutic interventions in conditions like cancer and neurodegeneration [10].

Conclusion

RNA sequencing (RNA-Seq) and single-cell RNA sequencing (scRNA-Seq) have dramatically advanced the study of gene expression, providing comprehensive insights into transcriptomes, cellular heterogeneity, and disease mechanisms. Microglia, as central nervous system immune cells, are critical for brain health, with their dysfunction contributing to neurodegenerative disorders. The integration of RNA-Seq data with genome-wide association studies (GWAS) helps identify causal genes. CRISPR-Cas9 technology offers precise gene editing for functional genomics and therapeutic applications, while adeno-associated virus (AAV) vectors facilitate efficient in vivo gene delivery. Induced pluripotent stem cells (iPSCs) serve as vital in vitro models for studying human diseases and drug screening. Proteomics complements transcriptomics by providing direct information on protein function and interactions. A multi-omics approach, combining genomics, transcriptomics, and proteomics, is essential for a holistic understanding of biological systems and disease complexity, accelerating biomarker discovery and targeted therapy development. Epigenetic modifications further regulate gene expression without altering DNA sequence, offering additional therapeutic targets. Machine learning algorithms are increasingly leveraged to analyze biological big data, transforming biomedical research through pattern identification and predictive modeling. Ultimately, translational research bridges basic science with clinical application, improving patient care through novel diagnostics and therapies.

References

1. Ramon P, Antonio G, D LPMdJ. Genomic Landscape of Metastatic Castration-Resistant Prostate Cancer in Patients Treated with First-Line Cabazitaxel. *Eur Urol*. 2023;84:588-597.

2. Ramon P, A ANYdJ, A JHdB. The Genomic Landscape of De Novo Metastatic Castration-Resistant Prostate Cancer. *Eur Urol Oncol*. 2023;6:574-583.

3. Ahmed MH, Jinlu L, Xujun H. Genomic and Transcriptomic Profiling of Metastatic Castration-Resistant Prostate Cancer Reveals Novel Therapeutic Vulnerabilities. *Mol Cancer Ther*. 2023;22:969-979.

4. Kyoung P, Chul HK, Jung HK. Single-Cell RNA Sequencing of Prostate Cancer Organoids Reveals Intratumoral Heterogeneity and Resistance Mechanisms to Antiandrogen Therapy. *Cells*. 2023;12:1867.

5. Emmanuel SA, Sun BK, Stephanie EG. Androgen Receptor Splice Variants and Their Role in Castration-Resistant Prostate Cancer. *J Clin Oncol*. 2020;38:1610-1620.

Cite this article: Vukovic KJ,(2025) Multi-Omics, Gene Editing, AI: Advancing Biomedical Research. Eur J Clin Oncol 07: 7. DOI:

6. Neal DS, Richard LD, Marina GP. Mechanisms of resistance to androgen receptor-targeted therapies in prostate cancer. *Nat Rev Clin Oncol*. 2022;19:5-21.

7. Ai SL, Jia HT, Stephanie LT. Gene Expression Profiling of Prostate Cancer: A Review of Prognostic and Predictive Biomarkers. *Cancers (Basel)*. 2021;13:2470.

8. Firas SHA, C EL, M CG. Overcoming Resistance to Androgen Receptor-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. *Front Oncol*. 2022;12:863212.

9. K GNMvdH, P MJWM, J RWBMvdB. The role of gene expression in predicting response to chemotherapy in metastatic castration-resistant prostate cancer. *Eur J Cancer*. 2020;129:111-122.

10. Niels GWA, P MLVdB, T SKCdW. Targeting the DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. *Eur Urol*. 2021;80:440-449.

Cite this article: Vukovic KJ,(2025) Multi-Omics, Gene Editing, AI: Advancing Biomedical Research. Eur J Clin Oncol 07: 7. DOI: